News
LCTX
0.4969
-0.62%
-0.0031
Weekly Report: what happened at LCTX last week (1209-1213)?
Weekly Report · 2d ago
Weekly Report: what happened at LCTX last week (1202-1206)?
Weekly Report · 12/09 11:31
Lineage Cell Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 12/04 11:25
Lineage Cell Therapeutics Price Target Raised to $9.00/Share From $7.00 by HC Wainwright & Co.
Dow Jones · 12/04 11:25
HC Wainwright & Co. Maintains Buy on Lineage Cell Therapeutics, Raises Price Target to $9
Benzinga · 12/04 11:16
Lineage Cell Therapeutics price target raised to $9 from $7 at H.C. Wainwright
TipRanks · 12/04 11:10
Weekly Report: what happened at LCTX last week (1125-1129)?
Weekly Report · 12/02 11:31
Weekly Report: what happened at LCTX last week (1118-1122)?
Weekly Report · 11/25 11:22
Insider Purchase: President and CEO of $LCTX (LCTX) Buys 40,000 Shares
Barchart · 11/22 18:24
Thursday Sector Laggards: Shipping, Biotechnology Stocks
NASDAQ · 11/21 17:01
Lineage Cell (LCTX) Loses -26.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
NASDAQ · 11/21 14:35
Lineage Therap Announces $66 Million Direct Offering
TipRanks · 11/20 22:29
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 11/20 21:10
Lineage Cell price target lowered to $2 from $3 at D. Boral Capital
TipRanks · 11/20 21:00
Lineage Cell Therapeutics Price Target Cut to $2.00/Share From $3.00 by D. Boral Capital
Dow Jones · 11/20 17:29
Lineage Cell Therapeutics Is Maintained at Buy by D. Boral Capital
Dow Jones · 11/20 17:29
D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Lowers Price Target to $2
Benzinga · 11/20 17:19
Lineage Cell Therapeutics tumbles after pricing $66M securities offering
Seeking Alpha · 11/20 13:30
Lineage Cell Therapeutics Entered Into Definitive Agreements With Certain Institutional Investors And With Broadwood Partners, L.P. For The Purchase And Sale Of Up To An Aggregate Of 39,473,688 Of Lineage's Common Shares And Accompanying Warrants To Purchase An Aggregate Of Up To 39,473,688 Of Lineage's Common Shares At A Combined Purchase Price Of $0.76 Per Common Share And Accompanying Common Warrant
Benzinga · 11/20 13:08
5 Stocks Retail Investors Are Most Bearish On At Mid-Day
Barchart · 11/20 13:06
More
Webull provides a variety of real-time LCTX stock news. You can receive the latest news about Lineage Cell The through multiple platforms. This information may help you make smarter investment decisions.
About LCTX
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.